SFFS
MYGN icon

Stonehage Fleming Financial Services’s Myriad Genetics MYGN Stock Holding History

Stonehage Fleming Financial Services’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-58,200
Closed -$1.12M – 258
2017
Q1 		$1.12M Sell
58,200
-43,300
-43% -$767K 0.07% 103
2016
Q4 		$1.69M Buy
+101,500
New +$1.84M 0.11% 86

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Stonehage Fleming Financial Services's MYGN Position: Q2 2017 in Review

Stonehage Fleming Financial Services sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 58,200 shares — an estimated $1.12M sold.

Stonehage Fleming Financial Services first reported a position in MYGN in Q4 2016 and held it in 2 quarters. The position peaked at $1.69M in Q4 2016. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Stonehage Fleming Financial Services reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Stonehage Fleming Financial Services sold 58,200 Myriad Genetics shares in Q2 2017, an estimated $1.12M.
  • Stonehage Fleming Financial Services first reported a position in Myriad Genetics in Q4 2016 and held it in 2 quarters.
  • Stonehage Fleming Financial Services's Myriad Genetics position peaked at $1.69M in Q4 2016.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Stonehage Fleming Financial Services's 13F filing for Q2 2017, filed 11 Oct 2019.